Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Liver health check: new drug tested in patients with impaired livers

NCT ID NCT05917938

First seen Feb 19, 2026 · Last updated May 23, 2026 · Updated 12 times

Summary

This study looked at how a single injection of the experimental drug NNC0194-0499 behaves in the body of people with various degrees of liver impairment and in healthy volunteers. The drug is being developed for fatty liver disease (NAFLD/NASH). 33 adults received one shot, and researchers measured drug levels and safety over 64 days. The goal was to understand how liver function affects the drug, not to treat the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • APEX Research

    München, 81241, Germany

  • Cardiomedicum Sp. z o.o.

    Krakow, 30-002, Poland

  • Summit Clinical Research s.r.o.

    Bratislava, 83101, Slovakia

  • Summit Clinical Research s.r.o.

    Malacky, 901 22, Slovakia

  • Uniwersyteckie Centrum Kliniczne (UCK)

    Gdansk, 80-214, Poland

Conditions

Explore the condition pages connected to this study.